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A B S T R A C T
Mitochondria are critical sources of hydrogen peroxide (H2O2), an important secondary messenger in mam-
malian cells. Recent work has shown that O2•-/H2O2 emission from individual sites of production in mi-
tochondria is regulated by protein S-glutathionylation. Here, we conducted the ﬁrst examination of O2•-/H2O2
release rates from cardiac and liver mitochondria isolated from mice deﬁcient for glutaredoxin-2 (GRX2), a
matrix-associated thiol oxidoreductase that facilitates the S-glutathionylation and deglutathionylation of pro-
teins. Liver mitochondria isolated from mice heterozygous (GRX2+/-) and homozygous (GRX2-/-) for glutar-
edoxin-2 displayed a signiﬁcant decrease in O2•-/H2O2 release when oxidizing pyruvate or 2-oxoglutarate. The
genetic deletion of the Grx2 gene was associated with increased protein expression of pyruvate dehydrogenase
(PDH) but not 2-oxoglutarate dehydrogenase (OGDH). By contrast, O2•-/H2O2 production was augmented in
cardiac mitochondria from GRX2+/- and GRX2-/- mice metabolizing pyruvate or 2-oxoglutarate which was
associated with decreased PDH and OGDH protein levels. ROS production was augmented in liver and cardiac
mitochondria metabolizing succinate. Inhibitor studies revealed that OGDH and Complex III served as high
capacity ROS release sites in liver mitochondria. By contrast, Complex I and Complex III were found to be the
chief O2•-/H2O2 emitters in cardiac mitochondria. These ﬁndings identify an essential role for GRX2 in regulating
O2•-/H2O2 release from mitochondria in liver and cardiac tissue. Our results demonstrate that the GRX2-medi-
ated regulation of O2•-/H2O2 release through the S-glutathionylation of mitochondrial proteins may play an
integral role in controlling cellular ROS signaling.
1. Introduction
Mitochondria are quantiﬁably the most important sites for ROS pro-
duction and have been documented to contain up to 12 O2•-/H2O2 pro-
ducing enzymes associated with nutrient metabolism [1]. High capacity
sites for ROS production include Complex III and OGDH in liver mi-
tochondria [2]. In skeletal muscle, the most important O2•-/H2O2 sources
are OGDH and PDH and Complexes I, II, and III [3]. By contrast, complex I
and III seem to be critical sources for ROS release in cardiac tissue [4,5].
Examination of the ROS forming capacity of individual sites of production
is vital since mitochondria utilize H2O2 as a secondary messenger. Indeed,
mitochondrial H2O2 is required to stimulate cell division, diﬀerentiation,
and growth and is required to regulate steroidogenesis, circadian rhythms,
T-cell function, and hematopoiesis [2]. Complex III is often regarded as the
main source of O2•-/H2O2 in cell signaling [6]. However, recent evidence
also indicates that other sites, like OGDH, which accounts for a substantial
fraction of the ROS formed in liver mitochondria, can potentially make a
major contribution to H2O2 signaling as well [2].
To serve as an eﬀective secondary messenger, H2O2 levels need to be
controlled through its production and degradation. This is important since
ROS can be damaging at high levels causing oxidative distress and tissue
damage [7]. The degradation of O2•- and H2O2 is facilitated by antioxidant
systems while production of either molecule is modulated by several
mechanisms. Proton leaks represent one possible mechanism for mod-
ulating mitochondrial ROS release [8]. Unfortunately, there is still no clear
consensus on the physiological importance of proton return in controlling
ROS formation. In addition, it has been suggested that the rate of mi-
tochondrial ROS production does not directly depend on protonmotive
force or the rate of respiration [9]. Redox signals mediated through pro-
tein S-glutathionylation has emerged as another potential mechanism for
the regulation of mitochondrial ROS emission. Work on the redox reg-
ulation of mitochondrial bioenergetics can be traced back to almost 20
years ago when it was found that the inhibition of Complex I correlates
with a depletion of glutathione (GSH) pools and the blocking of cysteine
residues [10]. It was later found that S-glutathionylation modiﬁes O2•-/
H2O2 release from Complex I and that GRX2 was required to regulate this
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process [11,12]. Moreover, it was documented that the conjugation and
removal of GSH from Complex I by GRX2 is sensitive to changes in mi-
tochondrial redox buﬀering capacity [11,13]. Studies have found that
GRX2 and S-glutathionylation are integral for modulating overall ROS
emission and phosphorylating respiration in response to changes in redox
poise [11,14]. The importance of GRX2 in mediating S-glutathionylation
reactions in mitochondria is underscored by the consequences associated
with a loss or deﬁciency in the enzyme. For example, GRX2 deﬁciency
leads to the development of cataracts, signs of heart disease, hypertension,
and perturbs embryonic development [11,15,16]. It has also recently been
shown to play a role in regulating mitochondrial morphology and low
GRX2 transcript levels correlates with development of heart disease in
humans [17]. This is associated with impaired mitochondrial ATP pro-
duction and higher than normal ROS production rates [11]. By contrast, its
overexpression protects from doxorubicin-induced cardiac injury and
prevents apoptosis [18]. Therefore, protein S-glutathionylation reactions
mediated by GRX2 are critical for modulating mitochondrial metabolism
and function in response to changes in redox poise.
A number of protein S-glutathionylation targets have been identiﬁed in
mitochondria [19]. However, only a few GRX2 targets have been docu-
mented so far and its function in controlling ROS release from the 12
available O2•-/H2O2 producing sites in mitochondria has not been thor-
oughly examined. Our group recently found that PDH and OGDH are
targeted for S-glutathionylation which modulates O2•-/H2O2 emission from
either enzyme complex [14]. Chemical inducers for S-glutathionylation,
diamide and disulﬁram, induced a ~90% decrease in ROS release from
PDH and OGDH, which was associated with conjugation of GSH to either
enzyme [14]. In addition, it was found that GRX2 can deglutathionylate
puriﬁed PDH and OGDH restoring native ROS release rates [14,20]. In the
present study, we proﬁled the ROS release rates of liver and cardiac mi-
tochondria isolated from GRX2 deﬁcient mice exposed to diﬀerent sub-
strate and inhibitor combinations. To our knowledge, this is the ﬁrst study
to perform a detailed assessment of the native O2•-/H2O2 release rates from
mitochondria deﬁcient in GRX2. In order to examine the eﬀect of GRX2
deﬁciency on native ROS release rates from diﬀerent sites, O2•-/H2O2
production was measured using mitochondria oxidizing diﬀerent sub-
strates and exposed to selective ROS release inhibitors (Fig. 1). To properly
measure ROS release rates from the electron transport chain exclusively,
mitochondria were supplemented with succinate only, which feeds elec-
trons directly into the ubiquinone pool of respiratory chain (Fig. 1). As-
sessment of ROS release rates from PDH and OGDH was achieved by
measuring O2•-/H2O2 emission from mitochondria oxidizing either pyr-
uvate or 2-oxoglutarate (Fig. 1). Various selective inhibitors for ROS re-
lease from OGDH and Complexes I, II, and III were also utilized. It was
found that GRX2 deﬁciency led to the development of diﬀerent ROS
emission proﬁles in liver and cardiac mitochondria which we attribute to
variances in substrate preference for O2•-/H2O2 production between the
two tissues. For example, GRX2 deﬁciency induced a signiﬁcant decrease
in mitochondrial ROS production in liver mitochondria oxidizing pyruvate
or 2-oxoglutarate but had the opposite eﬀect in mitochondria from cardiac
tissue. Intriguingly, liver mitochondria yielded high amounts of ROS when
oxidizing these substrates whereas succinate served as an important source
for O2•-/H2O2 production in cardiac mitochondria. The importance of
these ﬁndings in regard to understanding the importance of GRX2 and
protein S-glutathionylation in modulating ROS release in mitochondria
oxidizing diﬀerent nutrient sources is discussed herein.
2. Experimental
2.1. Animals and genotyping
Mice heterozygous for GRX2 were a gift from Dr. Mary-Ellen Harper
(Faculty of Medicine, University of Ottawa). GRX2 homozygotes and
heterozygotes were generated using the C57Bl6N mouse strain. All
experiments were approved by Memorial University's Animal Care and
Use committee and conducted according to institutional and Federal
animal care guidelines. Mice were housed in the animal care unit at
room temperature (~23 °C, 12 h (h) dark/12 h light cycle, lights on at
0700 h) and given free access to water and chow (Teklad Global 18%
Protein Rodent Diet, 2018). Age-matched male and female mice het-
erozygous for GRX2 were paired for breeding and the generation of
litters. At 3 weeks of age, male pups were ear notched for genotyping.
Mice were weighed weekly and euthanized at 8 weeks of age by cervical
dislocation under isoﬂurane anesthesia. Cardiac and liver tissue were
extracted for mitochondrial isolation.
DNA extraction for RT-PCR was carried out using the REDExtract-N-
Amp Tissue PCR Kit (Sigma-Aldrich) according to the manufacturer's
instructions. DNA was ampliﬁed using primer sequences for the Grx2
gene [5’-GAC CTA GCC TAC CAG ACT TGG CTG AAA TTT ATT C−3’
(forward), 5’-CAT AGA CAC TCT TCA CTT TCA AGC CCA CCC TC−3’
(reverse)]. Brieﬂy, the DNA extract was mixed with 1 µL of 0.5 µM Grx2
primer, 10 µL of REDExtract-N-Amp Tissue PCR Kit Reaction Mixture,
and nuclease-free water providing a ﬁnal reaction volume of 20 µL.
DNA sequences were then ampliﬁed using an Eppendorf Mastercycler
pro PCR System for 30 cycles. PCR samples were then electrophoresed
in a 1.5% w/v agarose gel containing SYBR Safe DNA Gel Stain (1/
10000 dilution, Fischer Scientiﬁc). DNA fragment size was estimated by
electrophoresing Trackit 100 bp DNA Ladder (Fisher Scientiﬁc).
Fig. 1. Experimental design for the assessment of the eﬀect of GRX2 deﬁciency on native
ROS release rates from diﬀerent sites of production. Oxidation of Krebs cycle linked
metabolites, pyruvate and 2-oxoglutarate, allows the assessment of ROS release rates
from pyruvate dehydrogenase (PDH) and 2-oxoglutarate (OGDH) and the electron
transport chain. Succinate was used to test ROS release from the electron transport chain
since it feeds electrons directly into the ubiquinone pool (Q pool), bypassing the Krebs
cycle. The site of action for the selective ROS release inhibitors (KMV; 3-methyl-2-oxo
valeric acid, rot; rotenone, A5; atpenin A5, myxo; myxothiazol), which allow the esti-
mation of rates of ROS release production from individual sites, are indicated in the
diagram. Sites for ROS production in the diﬀerent experimental systems are denoted with
a red star. Direction of electron ﬂow is indicated by a dotted arrow.
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Nucleotide sequences corresponding to the ampliﬁed Grx2 gene were
visualized with the Alpha Innotech ChemiImager Ready System. WT
mice produced a single nucleotide sequence that was 729 base pairs
(bp) in length while GRX2-/- mice produced a fragment 510 bp in size.
Samples collected from GRX2+/- mice contained both nucleotide
fragments (510 bp and 729 bp).
2.2. Preparation of mitochondria
All steps were performed on ice or 4 °C. After extraction, livers and
hearts were immediately placed in freshly prepared mitochondrial
isolation buﬀer containing mannitol (220 mM; to quench hydroxyl ra-
dical), EGTA (1 mM), sucrose (70 mM), and Hepes (10 mM) (pH 7.4,
abbreviated MESH buﬀer) supplemented with 0.5% fatty acid free BSA
(MESH-B). Note that we found in a previous study that this buﬀer
system does not induce the auto-oxidation of Amplex Ultra Red [21].
Livers were cut into small pieces, rinsed, and then minced on a Teﬂon
watch glass. Minced livers were then homogenized in 15 mL MESH-B
using the Potter-Elvejham method. Homogenates were centrifuged at
800×g for 9 min. The supernatant was collected and centrifuged at
10,000×g for 9 min to pellet mitochondria. The supernatant was dec-
anted, excess fat was wiped clean from the sides of the tubes, and then
mitochondrial pellets were washed in 15 mL MESH-B and centrifuged at
10,000×g for 9 min. The ﬁnal mitochondrial pellet was resuspended in
500 µL MESH giving a ﬁnal concentration of 15–20 mg/mL.
Hearts were initially cut into smaller pieces to wash away any ex-
cess blood. After several rinses, heart pieces were minced on a Teﬂon
watch glass. Minced hearts were homogenized in MESH-B containing 1
unit of protease (subtilisin A, to disrupt any myoﬁbers containing mi-
tochondria) using the Potter-Elvejham method. Homogenates were ﬁrst
centrifuged at 10,000×g for 9 min to remove subtilisin A. The pellet
was resuspended in 15 mL MESH-B and centrifuged at 800×g for
9 min. The supernatant was collected and centrifuged at 10,000×g for
9 min. The resulting mitochondrial pellet was resuspended in 100 µL
MESH providing a ﬁnal protein concentration of 6–8 mg/mL. Protein
content was quantiﬁed by Bradford Assay using BSA as a standard.
2.3. Measurement of O2•-/H2O2 release
Mitochondrial O2•-/H2O2 production was examined using the
Amplex Ultra Red (AUR) assay as described previously [2]. O2•- is often
considered the proximal ROS formed by mitochondria. However, it has
been documented that ﬂavin sites (either FAD or FMN) form a mixture
of O2•- and H2O2 [22,23]. In addition, any O2•- formed is quickly dis-
mutated to H2O2 by endogenous SOD. AUR cannot discriminate be-
tween H2O2 formed during nutrient oxidation or by the dismutation of
O2•-. Therefore, AUR measurements for ROS release by mitochondria
are deﬁned as the rate of O2•-/H2O2 release. Liver mitochondria and
cardiac mitochondria were ﬁrst diluted to 3 mg/mL and 1 mg/mL in
MESH, respectively, and then stored on ice. Liver and cardiac mi-
tochondria were then diluted to 0.3 mg/mL and 0.1 mg/mL in the wells
of a black 96-well plate containing MESH-B. Mitochondria were treated
with or without 3-methyl-2-oxo valeric acid (KMV, 10 mM), myx-
othiazol (4 µM), atpenin A5 (40 µM), or rotenone (4 µM) and incubated
for 5 min at 25 °C. Horseradish peroxidase (HRP, 3 U/mL), superoxide
dismutase (SOD, 25 U/mL), and AUR reagent (10 µM) were then added
to individual wells. Reactions were initiated by the addition of pyruvate
(50 µM)/malate (50 µM), 2-oxoglutarate (50 µM)/malate (50 µM), or
succinate (50 µM). Note that malate was added to complete the Krebs
cycle to ensure the full oxidation of pyruvate and 2-oxoglutarate al-
lowing for the measure of ROS release by PDH, OGDH, and the electron
transport chain. Succinate oxidation, on the other hand, by-passes the
Krebs cycle completely ensuring measurement of ROS released by the
electron transport chain only. Changes in ﬂuorescence were tracked at
excitation and emission wavelengths 565 nm/600 nm using a Spec-
tramax M2 microplate reader (Molecular Devices) for 5 min at 25 °C.
For genotype comparisons, O2•-/H2O2 release rates by GRX2+/- or
GRX2-/- mitochondria were expressed as a percentage of WT produc-
tion rates. Inhibitor eﬀects were expressed as a percent of control
(mitochondria not treated with O2•-/H2O2 release inhibitors).
2.4. Polarographic measurement of mitochondrial respiration
The diﬀerent states of respiration in mitochondria prepared from
liver and cardiac tissue was monitored using an Oxytherm electrode
system (Hansatech). Liver and cardiac mitochondria were diluted to
0.5 mg/mL and 0.1 mg/mL, respectively, in the Oxytherm electrode
chamber containing respiration buﬀer (220 mM mannitol, 70 mM su-
crose, 2 mM Hepes, 1 mM EGTA, 10 mM KH2PO4, 5 mMMgCl2, pH 7.4)
and allowed to equilibrate until a stable oxygen baseline was reached.
Pyruvate (10 mM) and malate (2 mM) were injected in the reaction
chamber to assess state 2 respiration. State 3 respiration (phosphor-
ylating respiration) was induced by adding ADP (1 mM). Oligomycin
(4 µg/mL), an inhibitor for ATP synthase and any contaminating
ATPases, was then injected into the reaction mixture to assess state 4
respiration (nonphosphorylating respiration – proton leaks). Oxygen
consumption not associated with the electron transport chain (e.g.
oxygenases) was measured by adding antimycin A (4 µM), a Complex III
inhibitor. Rates of mitochondrial respiration were normalized by sub-
tracting oxygen consumption not associated with the electron transport
chain (rate of consumption – oxygen consumed after antimycin A ad-
dition). Respiratory control ratios were calculated as the ratio of state 3
to state 4 respiration.
2.5. Immunoblot
Mitochondria were diluted to 1–3 mg/mL in Laemmli buﬀer and
then heated at 100 °C for 10 min. Ten to sixty micrograms of protein
were loaded in each well and then samples were electrophoresed
through either a 10% isocratic SDS gel [for detection of PDH, OGDH,
and protein glutathione mixed disulﬁdes (PSSG)] or a 12% isocratic
SDS gel (detection of GRX1 and GRX2). Note that for PSSG detection,
25 mM N-ethylmaleimide (NEM) was include in the isolation buﬀer,
including the homogenizing buﬀer, to preserve protein glutathione
adducts. This is in contrast to previous studies where it was only in-
cluded in Laemmli buﬀer after mitochondria had been isolated [24].
Once completed, proteins were transferred from the gels to ni-
trocellulose membranes by tank transfer. Membranes were stained with
Ponceau S and documented to ensure successful protein transfer. In
addition, Ponceau S stains served as the loading control for blots used
for PSSG detection. Membranes were rinsed with Tris-buﬀered saline
(TBS) containing 0.1% (v/v) Tween-20 (TBS-T) to remove the Ponceau
S stain and blocked for 1 h under constant agitation at room tempera-
ture with TBS-T containing 5% (w/v) non-fat skim milk. Membranes
were then washed twice with TBS-T and probed with anti-OGDH (20 µg
for liver, 10 µg for cardiac, 1/3000, Abcam), anti-PDH (20 µg for liver,
10 µg for cardiac, 1/3000, Abcam), anti-GRX1 (30 µg for liver, 60 µg for
cardiac, 1/2000, Abcam), anti-GRX2 (40 µg for liver, 1/500, Abcam),
anti-PSSG (20 µg for liver, 20 µg for cardiac, 1/500, Abcam), anti-SDHA
(1/3000, Santa Cruz), or anti-SOD2 (1/3000, Santa Cruz) diluted in
TBS-T containing 5% (w/v) BSA and 0.02% (w/v) NaN3. Membranes
were incubated in primary antibody overnight under constant agitation
at 4 °C. The speciﬁcity of the anti-PSSG antibody for S-glutathionylated
proteins was conﬁrmed by treating samples diluted in Laemmli buﬀer
with 2% (v/v) β-mercaptoethanol. Membranes were then washed twice
in TBS-T and probed with anti-mouse and anti-rabbit horseradish per-
oxidase conjugate secondary antibodies (1/3000, Santa Cruz, diluted in
blocking solution) for 1 h at room temperature under constant agita-
tion. Bands were visualized using WestPico Super Signal Chemilumi-
nescent substrate and ImageQuant LAS 4000. Band intensities were
quantiﬁed using ImageJ software.
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2.6. BioGEE switch assays
The degree of PDH and OGDH S-glutathionylation in liver mi-
tochondria was assayed using the BioGEE switch assay as described
previously with a few modiﬁcations (Fig. 6) [14,25]. Liver tissue from
WT and GRX2-/- mice was homogenized and mitochondria were iso-
lated as described above except 25 mM NEM was included in every
step. Upon isolation, mitochondria were resuspended in MESH con-
taining 25 mM NEM. For the biotin switch assays, mitochondria were
diluted to 4 mg/mL in 100 µL of lysis buﬀer containing 25 mM NEM
and incubated for 10 min at 37 °C. Excess NEM was removed using Zeba
micro spin desalting columns (ThermoFisher). Samples were then col-
lected and treated with 5 mL dithiothreitol (DTT) to reduce any protein-
glutathione adducts. Samples were then desalted as described above
and treated with biotinylated glutathione ethyl ester (BioGEE; 1 mM)
and disulﬁram (1 mM; an S-glutathionylation catalyst) and incubated
for 30 min at 25 °C. For control experiments, BioGEE and disulﬁram
treated samples were also supplemented with 2% (v/v) β-mercap-
toethanol to reduce BioGEE-modiﬁed proteins. Samples were supple-
mented with 50 µL of streptavidin-modiﬁed magnetic beads (Dyna-
beads; Invitrogen) and incubated for 2 h at room temperature under
constant agitation. Beads were then magnetically separated from su-
pernatant using a magnetic rack (Biorad), washed twice with PBS, and
then heated at 100 °C for 15 min to separate proteins from antibodies.
The beads were removed and the resulting supernatant was treated
with Laemmli buﬀer and electrophoresed for immunoblot as described
Fig. 2. Impact of GRX2 deletion on the mitochondrial S-glutathionylated proteome and the expression of GRX1. A. Genotypic characterization of mouse litters. RNA was extracted
from ear notches and subjected to PCR analysis for the presence of the full length or truncated forms of the Grx2 gene. B. Immunoblot analysis conﬁrming the partial knockout and
complete abolishment of GRX2. Assessment of GRX2 protein levels was conducted on mitochondria isolated from liver tissue. SDH subunit A served as the loading control. C. Depletion or
abolishment of GRX2 does not induce a compensatory increase in GRX1 in cardiac or liver tissue. Band intensities were quantiﬁed by ImageJ. SDH subunit A served as the loading control.
n = 3, mean± SEM. 1-way ANOVA Fisher's LSD post-hoc test. D. GRX2+/- and GRX2-/- do not display a signiﬁcant change in overall body weight when compared to WT littermates. n
= 12–21, mean± SEM, 1-way ANOVA Fisher's LSD post-hoc test. E. Partial ablation of the Grx2 gene induces a signiﬁcant increase in the overall number of S-glutathionylated proteins in
cardiac and liver mitochondria. Samples were electrophoresed under reducing (+ 2% v/v β-mercaptoethanol) or nonreducing (no β-mercaptoethanol) and probed for the presence of S-
glutathionylated proteins using protein-glutathione disulﬁde (PSSG) anti-serum. n = 3, mean±SEM. 1-way ANOVA Fisher's LSD post-hoc test.
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above. The E2 subunit for OGDH and PDH was detected using anti-
DLST anti-serum (DLST; dihydrolipoamide succinyl-transferase, E2
subunit for OGDH, 1/2000; Abcam) and anti-PDH cocktail (1/2000;
Abcam), respectively. Immunoreactive bands were visualized as de-
scribed above.
2.7. Data analysis
Amplex Ultra Red assays were performed 5 times and in duplicate.
Polarographic measure of mitochondrial respiration was conducted 4–5
times and in duplicate. Immunoblots were conducted in duplicate or
triplicate and densitometry normalized to loading controls. ROS release
results were normalized to paired control values to estimate the percent
change in O2•-/H2O2 formation following inhibitor treatment which can
limit power for analysis. All results were analyzed using GraphPad
Prism 6 software using two-tailed paired student T-Test or 1-way
ANOVA with Fisher's LSD posthoc test. * or #; p≤ 0.05, ** or ##; p≤
0.01, *** or ###; p ≤ 0.001.
3. Results
3.1. GRX2 deﬁciency does not induce a compensatory increase in Grx1
Fig. 2A demonstrates that GRX2 mouse litters contained either the
full length and/truncated Grx2 gene, pointing to the successful knock-
down (GRX2+/-) or out (GRX2-/-) of the protein. Identiﬁcation of WT,
GRX2+/-, or GRX2-/- mice was conducted by immunoblotting for
GRX2 protein in liver mitochondria (Fig. 2B). GRX1 has been reported
to localize to the intermembrane space of mitochondria where it reg-
ulates protein import and redox signaling [26]. Thus, we decided to test
if GRX2 deﬁciency results in a compensatory increase in GRX1. Im-
munoblot analysis revealed no signiﬁcant changes in GRX1 protein le-
vels even though a few samples displayed a slight increase or decrease
in band intensity (Fig. 2C). Moreover, previous studies have demon-
strated that the ablation or overexpression of the Grx2 gene does not
induce a compensatory increase in thioredoxin-2 [11,18,27]. The
physiological and anatomical impact of the absence of GRX2 was
characterized in two previous studies [11,27]. Knockout of GRX2 does
not change feeding behavior or linear growth and weight gain. Fig. 2D
conﬁrms that weight gain does not signiﬁcantly change in mice
heterozygous or homozygous for GRX2. It has been demonstrated pre-
viously that GRX2 deletion increases the overall number of S-glu-
tathionylated proteins in cardiac mitochondria [11]. Here, we found
that the partial deletion of GRX2 also augmented protein S-glutathio-
nylation (Fig. 2E). Performing the electrophoresis in the presence of β-
mercaptoethanol (reducing conditions) substantially decreased the in-
tensity of these bands conﬁrming that the protein S-glutathionylation
adduct anti-serum is speciﬁc for proteins modiﬁed by glutathione.
3.2. Eﬀect of GRX2 deﬁciency on ROS release during the oxidation of
pyruvate and 2-oxoglutarate
Our group has reported that OGDH and Complex III are high capacity
sites for ROS release in liver mitochondria, accounting for almost ~90% of
the total O2•-/H2O2 formed during the oxidation of pyruvate or 2-ox-
oglutarate [2]. Therefore, we decided to test the impact of GRX2 deﬁ-
ciency on production from these sites in liver mitochondria ﬁrst. As shown
in Fig. 3A, ROS release was signiﬁcantly lower in liver mitochondria iso-
lated form mice heterozygous or homozygous for GRX2. Next, we used
KMV and myxothiazol to determine if OGDH and Complex III served as
high capacity sites for ROS release. For this, we used a method employed
by our group and others to examine the ROS release rates of individual
sites of production [2,28]. It was shown previously that KMV is a strong
and speciﬁc allosteric inhibitor for O2•-/H2O2 production by OGDH [28].
Our group has found that KMV can induce a ~90% decrease in ROS
production by liver mitochondria metabolizing pyruvate or 2-oxoglutarate
[2]. KMV (10 mM) induced a ~85% decrease in ROS emission from WT,
GRX2+/-, or GRX2-/- liver mitochondria metabolizing either pyruvate or
2-oxoglutarate (Fig. 3B). Since KMV also lowers NADH production, the
decrease in ROS release during 2-oxoglutarate and pyruvate oxidation
could also be associated with diminished electron ﬂow through the re-
spiratory chain (Fig. 1). We decided to conduct the same assays with
mitochondria treated with myxothiazol, which inhibits ROS production
from Complex III by binding the QO binding site preventing semiquinone
production. Our group reported previously that Complex III accounts for
~45% of the ROS release from liver mitochondria [2]. We had also found
in the same study that rotenone elicits a similar eﬀect (decreases ROS
release by ~45%), conﬁrming that Complex III is a major ROS producer in
liver cells [2]. In addition, in the same previously published study, it was
found that treating liver mitochondria with both rotenone and KMV or
Fig. 3. Loss of GRX2 decreases pyruvate and 2-
oxoglutarate induced O2•-/H2O2 release from
liver mitochondria. A. O2•-/H2O2 release was ex-
amined in mitochondria prepared from the livers of
WT, GRX2+/-, and GRX2-/- mice oxidizing pyruvate
or 2-oxoglutarate. Mitochondria (0.3 mg/mL) were
diluted in reaction buﬀer containing either pyruvate
(50 µM) or 2-oxoglutarate (50 µM) and malate
(50 µM) and the production of H2O2 was measured
using AUR reagent. n = 5, mean±SEM. 1-way
ANOVA Fisher's LSD post-hoc test. B. Examination of
the high capacity site(s) for O2•-/H2O2 release in liver
mitochondria. Mitochondria (0.3 mg/mL) were pre-
incubated in KMV (10 mM) or myxothiazol (4 µM) in
reaction buﬀer and then H2O2 production was mea-
sured using AUR and pyruvate (50 µM) or 2-ox-
oglutarate (50 µM) and malate (50 µM). n = 5,
mean± SEM. 1-way ANOVA Fisher's LSD post-hoc
test.
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rotenone and ATP decreased ROS release by ~90%. Myxothiazol induced
a ~45% decrease in ROS production in mitochondria oxidizing pyruvate
and an almost 50% decrease in samples metabolizing 2-oxoglutarate
(Fig. 3B). Therefore, based on the cumulative KMV and myxothiazol ef-
fects, OGDH (and to a lesser extent PDH) and Complex III could potentially
account for up to ~90% of the ROS release from liver mitochondria. The
other 10% is likely contributed by other sites [2].
Next, we conducted similar experiments with cardiac mitochondria. To
our surprise the ROS release proﬁle in cardiac mitochondria was com-
pletely diﬀerent from the one observed with liver mitochondria. ROS
production rates were signiﬁcantly increased in GRX2+/- and GRX2-/-
cardiac mitochondria oxidizing pyruvate (Fig. 4A). Similar observations
were made with mitochondria oxidizing 2-oxoglutarate (Fig. 4A). Next,
the source of the increase in ROS production during pyruvate and 2-ox-
oglutarate metabolism was tested. Mitochondria were treated with either
KMV or myxothiazol. Surprisingly, KMV exposure induced a signiﬁcant
increase in ROS release from WT, GRX2+/-, and GRX2-/- cardiac mi-
tochondria oxidizing pyruvate (Fig. 4B). This eﬀect is attributed to
blockage of Krebs cycle metabolism and the accumulation of NADH and
metabolites which can augment ROS release from the electron transport
chain. Myxothiazol also induced a signiﬁcant increase in O2•-/H2O2 release
from mitochondria prepared from all three genotypes. However, no dif-
ferences in ROS production were observed in the diﬀerent treatment
groups during pyruvate oxidation. Similar experiments were conducted
with mitochondria metabolizing 2-oxoglutarate. (Fig. 4B). Myxothiazol
augmented mitochondrial ROS release while KMV did not have an eﬀect
(Fig. 4B). Myxothiazol is known to lower ROS release from Complex III by
blocking semiquinone formation. However, some other studies have de-
monstrated that myxothiazol can actually augment ROS release when
substrates that form NADH are metabolized in rat heart and brain mi-
tochondria [29]. This eﬀect is attributed to the blockage of electron ﬂow
through the respiratory chain increasing ROS release from sites of for-
mation upstream from Complex III like Complex I, which is typically re-
garded as a major source of O2•-/H2O2 in cardiac mitochondria [30].
3.3. GRX2 deﬁciency alters PDH and OGDH protein levels in liver and
cardiac mitochondria
The rate of ROS genesis is heavily inﬂuenced by the concentration of
the electron donating site [31]. Thus, we tested the impact of GRX2
deﬁciency on the protein levels of PDH and OGDH. Notable diﬀerences
in the expression of the diﬀerent subunits for PDH were observed.
Fig. 5A shows that there no signiﬁcant change in the level of the E1
subunit for OGDH in liver mitochondria from GRX2+/- or GRX2-/-
mice relative to control. The diﬀerent subunits for PDH displayed a
more drastic shift in expression. Indeed, the E1, E2, and E3 subunits for
PDH displayed signiﬁcant increases in GRX2-/- mitochondria when
compared to WT samples (Fig. 5B). An almost 2-fold increase in ex-
pression of the E2 subunit (top band) was observed in GRX2-/- mi-
tochondria and ~5-fold increase was recorded for the E1 and E3 sub-
units. No signiﬁcant changes in the expression of all three subunits was
observed in the GRX2+/-. OGDH and PDH have been documented to
undergo S-glutathionylation in diﬀerent tissues [10,14,32]. Therefore,
we decided to test if the decrease in ROS release in liver mitochondria
from GRX2 deﬁcient mice was associated with an increase in the S-
glutathionylation of either enzyme. To test this, we conducted a BioGEE
switch assay where sites for S-glutathionylation are modiﬁed with a
glutathione analog conjugated to biotin allowing for enzyme im-
munocapture (Fig. 6). As shown in Fig. 6, stronger immunoreactive
bands corresponding to the E2 subunit of PDH were detected in mi-
tochondrial samples collected from GRX2-/- mice. Notably, we were
also able to successfully modify the E2 subunit of PDH with BioGEE in
WT liver samples indicating that a small fraction of the total PDH pool
may be S-glutathionylated in isolated mitochondria (Fig. 6). Similar
observations were made for OGDH (Fig. 6). However, in this particular
case we only detected BioGEE-modiﬁed E2 subunit corresponding to
OGDH in mitochondria enriched from GRX2-/- liver. Reduction of the
disulﬁde bridge between BioGEE and the E2 subunit with β-mercap-
toethanol before immunoprecipitation decreased or abolished the pre-
sence of immunoreactive bands corresponding to the E2 subunit of PDH
or OGDH (Fig. 6). Collectively, these results demonstrate that deletion
of the Grx2 gene augments the protein levels of PDH. Furthermore, our
ﬁndings show that PDH and OGDH are targets for S-glutathionylation in
vitro and that the absence of GRX2 augments the protein S-glutathio-
nylation of either protein complex in isolated liver mitochondria.
Next, the protein levels for PDH and OGDH were examined in car-
diac mitochondria. A trend for a decrease in the protein levels of the E1
subunit for OGDH was observed in GRX2+/- and GRX2-/- mitochon-
dria (Fig. 7A). Signiﬁcant decreases in the E1 and E3 subunits for PDH
cardiac mitochondria from GRX2+/- and GRX2-/- were also recorded
(Fig. 7B). In addition, it was found that the E2 subunit for PDH dis-
played a small but signiﬁcant decrease but only in GRX2-/- cardiac
Fig. 4. Loss of GRX2 increases pyruvate and 2-
oxoglutarate induced O2•-/H2O2 release from
cardiac mitochondria. A. O2•-/H2O2 release was
examined in mitochondria prepared from the hearts
of WT, GRX2+/-, and GRX2-/- mice oxidizing pyr-
uvate or 2-oxoglutarate. Mitochondria (0.1 mg/mL)
were diluted in reaction buﬀer containing either
pyruvate (50 µM) or 2-oxoglutarate (50 µM) and
malate (50 µM) and the production of H2O2 was
measured using AUR reagent. n = 5, mean±SEM.
1-way ANOVA Fisher's LSD post-hoc test. B.
Examination of the high capacity site(s) for O2•-/
H2O2 release in liver mitochondria. Mitochondria
(0.1 mg/mL) were preincubated in KMV (10 mM) or
myxothiazol (4 µM) in reaction buﬀer and then H2O2
production was measured using AUR and pyruvate
(50 µM) or 2-oxoglutarate (50 µM) and malate
(50 µM). n = 5, mean± SEM. 1-way ANOVA
Fisher's LSD post-hoc test.
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mitochondria (Fig. 7B). Thus, despite the decrease in PDH and OGDH,
ROS production rates are still signiﬁcantly higher in GRX2+/- and
GRX2-/- mitochondria. Collectively, these ﬁndings demonstrate that
the partial absence or complete loss of GRX2 has opposing eﬀects in
liver and cardiac mitochondria.
3.4. GRX2 deﬁciency augments succinate-driven O2•-/H2O2 production
Next, the impact of GRX2 deﬁciency on O2•-/H2O2 formation by the
respiratory chain was examined. For this, succinate served as the sole
carbon source for respiration which bypasses the Krebs cycle donating
electrons to the ubiquinone pool, negating ROS release from PDH and
OGDH (Fig. 1). Fig. 8A demonstrates that succinate-driven ROS pro-
duction was signiﬁcantly higher in GRX2+/- and GRX2-/- mitochon-
dria from liver and cardiac tissue. Next, ROS production by diﬀerent
sites in the electron transport chain was examined. Liver mitochondria
were treated with atpenin A5, myxothiazol, or rotenone to determine
which site of production was aﬀected by GRX2 depletion. Atpenin A5
binds the ubiquinone binding pocket in Complex II (succinate dehy-
drogenase) blocking electron ﬂow to Complex I or III during succinate
oxidation (Fig. 1). Rotenone binds the ubiquinone binding pocket in
Complex I and thus serves as a means to determine how much ROS is
formed during reverse electron ﬂow from succinate (Fig. 1). As shown
in Fig. 8B, inclusion of atpenin A5 induced a small but signiﬁcant de-
crease in O2•-/H2O2 formation in liver mitochondria from all three
genotypes. Inclusion of myxothiazol induced a more signiﬁcant de-
crease in ROS production by liver mitochondria (Fig. 8B). Finally, in-
clusion of rotenone did not alter O2•-/H2O2 formation indicating Com-
plex I is not a signiﬁcant source of ROS in liver mitochondria. These
results conﬁrm that complex III is an important ROS source and com-
plex I is not a producer in liver mitochondria. Next, the eﬀect of the
diﬀerent inhibitors on O2•-/H2O2 production in WT and GRX2 deﬁcient
cardiac mitochondria was tested. Inclusion of atpenin A5 induced a
robust decrease in ROS production in all three genotypes (Fig. 8B).
Intriguingly, the eﬀect was much larger in cardiac mitochondria iso-
lated from GRX2+/- and GRX2-/- mice. In GRX2+/- and GRX2-/-
mitochondria, atpenin A5 decreased ROS production by ~85% whereas
in WT samples it was lowered by ~70% (Fig. 8B). A similar eﬀect was
observed in samples treated with myxothiazol (Fig. 8B). Finally, rote-
none decreased ROS production by cardiac mitochondria isolated from
WT, GRX2+/-, and GRX2-/- mice by ~85% but no diﬀerences were
observed between the genotypes. These results indicate Complex I and
potentially Complex III are important ROS sources in cardiac mi-
tochondria, an observation consistent with previous ﬁndings [5].
Fig. 5. Ablation of GRX2 induces a signiﬁcant increase in PDH protein levels in liver mitochondria. A. Immunoblot analysis of the levels of OGDH using E1 subunit anti-serum.
Band intensities were quantiﬁed by ImageJ. MnSOD served as the loading control. n = 3, mean±SEM. 1-way ANOVA Fisher's LSD post-hoc test. B. Immunoblot analysis of the levels of
E1, E2, and E3 subunits using PDH antibody cocktail. MnSOD served as the loading control. Band intensities were quantiﬁed by ImageJ. n = 3, mean± SEM. 1-way ANOVA Fisher's LSD
post-hoc test.
Fig. 6. E2 subunit of PDH and OGDH displays a
higher degree of S-glutathionylation in GRX2
deﬁcient liver mitochondria. Liver mitochondria
were ﬁrst treated with NEM to block exposed thiols
and then protein glutathione mixed disulﬁdes were
reduced with DTT. The newly exposed protein cy-
steine thiols previously modiﬁed by glutathione were
then re-glutathionylated with biotinylated glu-
tathione ethyl ester (BioGEE) with chemical S-glu-
tathionylation catalyst disulﬁram. Samples were also
treated with β-mercaptoethanol to remove the
BioGEE group to conﬁrm antibody speciﬁcity for the
immunocapture and immunoblot. Proteins were then
immunoprecipitated using streptavidin beads and
probed for the E2 subunit of OGDH and PDH by
Western blot. Samples treated with β-mercap-
toethanol (βME; reducing conditions) prior to strep-
tavidin immunocapture served as the control. n = 3.
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3.5. GRX2 deﬁciency alters respiration and oxidative phosphorylation
Mitochondrial O2•-/H2O2 production and release relies on the same
electron transfer pathways that are used to make ATP. Therefore, the
impact of a deﬁciency or absence in GRX2 on the bioenergetics of liver
and cardiac mitochondria was examined. Liver mitochondria from mice
heterozygous for GRX2 displayed a signiﬁcant increase in state 3
(phosphorylating) respiration (Fig. 9A). Liver mitochondria prepared
from GRX2-/- mice did not display any change phosphorylating re-
spiration when compared to WT samples (Fig. 9A). However, GRX2-/-
liver mitochondria did show small but signiﬁcant change in respiration
associated with proton leaks (state 4 respiration). Next, we calculated
the respiratory control ratio (RCR), a proxy measure for the eﬃciency
of ATP production in mitochondria. The signiﬁcant decrease in proton
leaks augmented the coupling eﬃciency for GRX2-/- mitochondria,
increasing its ATP forming capacity (Fig. 9A). By contrast, GRX2+/-
mitochondria displayed no signiﬁcant change in RCR relative to WT
mitochondria. We then conducted similar experiments with cardiac
mitochondria prepared from WT and GRX2 deﬁcient mice. Interest-
ingly, the absence of GRX2 had the opposite eﬀect on these mi-
tochondria. Mitochondria collected from the cardiac tissue of GRX2+/-
and GRX2-/- mice displayed ~50% decrease in state 3 respiration
(Fig. 9B). State 2 and 4 respiration was also signiﬁcantly decreased in
GRX2-/- cardiac mitochondria (Fig. 9B). Overall, these results demon-
strate that GRX2 has opposing regulatory eﬀects on mitochondrial re-
spiration and oxidative phosphorylation in liver and cardiac tissue.
3.6. Absolute ROS release rates for liver and cardiac mitochondria
oxidizing diﬀerent substrates
The results collected above indicate that the loss of GRX2 has dif-
ferential eﬀects on ROS production in liver and cardiac mitochondria.
In liver mitochondria, loss of GRX2 lowered pyruvate and 2-ox-
oglutarate driven O2•-/H2O2 production whereas it had the opposite
Fig. 7. Loss of GRX2 induces a signiﬁcant decrease in PDH protein levels in cardiac mitochondria. A. Immunoblot analysis of the levels of OGDH using E1 subunit anti-serum. Band
intensities were quantiﬁed by ImageJ. MnSOD served as the loading control. n = 3, mean± SEM. 1-way ANOVA Fisher's LSD post-hoc test. B. Immunoblot analysis of the levels of E1, E2,
and E3 subunits using PDH antibody cocktail. MnSOD served as the loading control. Band intensities were quantiﬁed by ImageJ. n = 3, mean± SEM. 1-way ANOVA Fisher's LSD post-hoc
test.
Fig. 8. Partial loss or ablation of GRX2 induces a
signiﬁcant increase in O2•-/H2O2 release from liver
and cardiac mitochondria oxidizing succinate. A.
Liver (0.3 mg/mL) and cardiac (0.1 mg/mL) mi-
tochondria were diluted in reaction buﬀer containing
succinate (50 µM) and the production of H2O2 was
measured using AUR reagent. n = 5, mean±SEM.
1-way ANOVA Fisher's LSD post-hoc test. B.
Examination of the high capacity site(s) for O2•-/
H2O2 release in liver mitochondria oxidizing succi-
nate. Mitochondria (0.3 mg/mL) were preincubated
in KMV (10 mM) or myxothiazol (4 µM) in reaction
buﬀer and then H2O2 production was measured
using AUR and pyruvate (50 µM) or 2-oxoglutarate
(50 µM) and malate (50 µM). n = 5, mean± SEM. 1-
way ANOVA Fisher's LSD post-hoc test. n = 4,
mean± SEM, 2-way ANOVA Fisher's LSD post-hoc
test.
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eﬀect in samples isolated from cardiac tissue (Figs. 3 and 4). By con-
trast, the absence of GRX2 augmented ROS production by succinate
oxidation in liver and cardiac mitochondria (Fig. 8). Unfortunately, we
were unable to identify the site responsible for enhancing succinate
driven ROS production in liver mitochondria. In addition, we were
unable to identify which site(s) were responsible for ROS formation in
cardiac mitochondria oxidizing Krebs cycle linked sustrates. We rea-
soned that these discrepancies can be partially attributed to diﬀerences
in ROS producing capacity of individual sites in liver and cardiac mi-
tochondria. In this study, we used physiological substrate concentra-
tions (50 µM) to stimulate ROS production which may allow for dif-
ferences in the rate of formation in cardiac and liver mitochondria to be
measured. First, we found that succinate is a poor substrate for ROS
production in liver mitochondria when compared to cardiac tissue
(Table 1). Indeed, cardiac mitochondria from WT or GRX2 deﬁcient
mice produced ~4-fold more O2•-/H2O2 than liver mitochondria when
oxidizing succinate (Table 1). Also, the absolute rate for ROS release
was ~2-fold higher in cardiac or liver mitochondria from GRX2 deﬁ-
cient mice (Table 1). The rate for pyruvate driven ROS production was
~5-fold higher in WT liver mitochondria when compared to cardiac
and ~2-fold higher in mitochondria from GRX2 deﬁcient mice
(Table 2). The absence of GRX2 also signiﬁcantly lowered ROS release
from liver mitochondria oxidizing pyruvate and had the opposite eﬀect
in cardiac mitochondria. Similar results were observed with liver and
cardiac mitochondria metabolizing 2-oxoglutarate. Indeed, O2•-/H2O2
emission in liver mitochondria isolated from WT mice oxidizing 2-ox-
oglutarate was ~4.5-fold higher than cardiac mitochondria (Table 3).
In addition, rates of production in GRX2+/- and GRX2-/- were ~2.5
fold higher in liver mitochondria when compared to cardiac (Table 3).
Finally, the loss of GRX2 increased ROS release in cardiac mitochondria
oxidizing 2-oxoglutarate. By contrast, GRX2 deﬁciency had the opposite
eﬀect on liver mitochondria, lowering ROS release during 2-ox-
oglutarate metabolism. Overall, this demonstrates that liver and cardiac
tissue display a certain level of speciﬁcity in terms of which sites will
serve as the major sources of ROS.
4. Discussion
The present ﬁndings show that GRX2 regulates O2•-/H2O2 release
from liver and cardiac mitochondria. This is the ﬁrst study of its kind to
demonstrate that GRX2 is required to control the production of H2O2,
an observation that has strong implications for how the formation of
this secondary messenger for mitochondria-to-cell communication is
regulated. It has been put forth that cellular redox switches serve as an
interface between changes in the environment (the exposome – e.g.
nutrient availability) and the genome/transcriptome/metabolome [33].
In mitochondria, these redox relays are inﬂuenced by nutrient oxida-
tion which alters mitochondrial redox poise through H2O2 and NADPH
production [34]. Reversible oxidation of cysteine switches on mi-
tochondrial sources of ROS in response to changes in the exposome has
been proposed to regulate mitochondria-to-cell signaling [35]. Our
ﬁndings indicate that GRX2 forms part of this redox interface, mod-
ulating how much O2•-/H2O2 is formed by high capacity ROS release
sites in liver and cardiac mitochondria in response to changes in nu-
trient availability.
Fig. 9. Impact of GRX2 deletion on mitochondrial
respiration and oxidative phosphorylation capa-
city. A. Liver mitochondria (0.5 mg/mL) were di-
luted in 1 mL of respiration buﬀer in the Oxytherm
electrode reaction chamber. Once a stable baseline
was reached, the diﬀerent states of respiration were
measured. State 2 respiration was induced by adding
pyruvate (10 mM) and malate (2 mM) followed by
the induction of state 3 respiration (injection of ADP
to a ﬁnal concentration of 1 mM). State 4 respiration
was induced by adding oligomycin (4 µg/mL).
Finally, respiration was stopped by the addition of
antimycin A (4 µM). n = 3–5, mean± SEM. 1-way
ANOVA Fisher's LSD post-hoc test. B. Cardiac mi-
tochondria (0.1 mg/mL) were diluted in 1 mL of re-
spiration buﬀer in the Oxytherm electrode reaction
chamber. Once a stable baseline was reached, the
diﬀerent states of respiration were measured. State 2
respiration was induced by adding pyruvate (10 mM)
and malate (2 mM) followed by the induction of state
3 respiration (injection of ADP to a ﬁnal concentra-
tion of 1 mM). State 4 respiration was induced by
adding oligomycin (4 µg/mL). Finally, respiration
was stopped by the addition of antimycin A (4 µM). n
= 4–5, mean±SEM. 1-way ANOVA Fisher's LSD
post-hoc test.
Table 1
Comparison of the O2•-/H2O2 emission rates from cardiac and liver mitochondria oxi-
dizing succinate. 2-way ANOVA with a Fisher's LSD post-hoc test. n = 5, mean± SEM.
pmol min−1 mg of protein−1.
WT GRX2+/- GRX2-/-
Liver 107.27± 14.98 195.27± 28.15* 173.83± 31.41*
Cardiac 389.11± 46.84# 759.37± 133.37**, # 699.88± 134.51**, #
* corresponds to comparison between genotype, # corresponds to comparison between
tissues within genotype. p ≤ 0.05 = * or #, p ≤ 0.01 = **.
Table 2
Comparison of the O2•-/H2O2 emission rates from cardiac and liver mitochondria oxi-
dizing pyruvate. 2-way ANOVA with a Fisher's LSD post-hoc test. n = 4, mean±SEM.
pmol min-1 mg of protein-1.
WT GRX2+/- GRX2-/-
Liver 308.72± 43.75 203.64±29.71* 193.61± 18.04*
Cardiac 44.96± 21.05## 107.05±20.02*, # 81.20± 1.51*, #
* corresponds to comparison between genotype, # corresponds to comparison between
tissues within genotype. p ≤ 0.05 = * or #, p ≤ 0.01 = ##.
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4.1. GRX2 deﬁciency has diﬀerential eﬀects on pyruvate and 2-
oxoglutarate driven ROS production in liver and cardiac mitochondria
O2•-/H2O2 emission is inﬂuenced by mitochondrial redox poise and
changes in glutathione buﬀering capacity. PDH and OGDH have been
identiﬁed as mitochondrial redox sensors which adjust their enzymatic
activity and ROS output in response to changes in mitochondrial redox
buﬀering capacity [14,36,37]. Our group demonstrated recently that
this redox sensing capacity is related to the protein S-glutathionylation
of PDH and OGDH in liver mitochondria and that conjugation of glu-
tathione to either enzyme complex alters ROS release during forward
and reverse electron ﬂow [14,20]. Protein S-glutathionylation de-
creased O2•-/H2O2 emission from both enzyme complexes and puriﬁed
GRX2 can reverse these eﬀects [14,20]. In the present study, it was
found that a deﬁciency in GRX2 signiﬁcantly decreased ROS release in
liver mitochondria oxidizing pyruvate and 2-oxoglutarate. BioGEE
switch assays revealed that the E2 subunit of OGDH and PDH exhibited
increased protein S-glutathionylation in liver mitochondria isolated
from GRX2 deﬁcient mice. This conﬁrms observations from previous
studies demonstrating that the E2 subunit of OGDH and PDH is targeted
for S-glutathionylation [14,38]. Here, we have extended on these ob-
servations by demonstrating that endogenously expressed GRX2 is re-
quired to control ROS release from PDH and OGDH in isolated mi-
tochondria. It should be noted though that the results collected in this
study were done with isolated mitochondria which may not be a direct
reﬂection of mitochondrial function in vivo. However, this perceived
limitation does not negate the novelty of our ﬁndings which clearly
demonstrate that endogenously expressed GRX2 is required to control
ROS release from these enzymes through protein S-glutathionylation.
Taken together, OGDH and PDH are targets for protein S-glutathiony-
lation and GRX2 may be required to modulate how much ROS is re-
leased from these two enzymes for mitochondria-to-cell signaling in
liver.
Most studies invested in deciphering the impact of protein S-glu-
tathionylation on mitochondrial function and total ROS release have
been carried out in cardiac tissue. Complex I in cardiac mitochondria
was identiﬁed as one of the ﬁrst sites in mitochondria to undergo
protein S-glutathionylation [39]. Several studies have demonstrated
that S-glutathionylation alters native ROS release rates from Complex I
[12,39–41]. In addition, GRX2 is required to conjugate and remove
glutathione from Complex I in response to changes in mitochondrial
redox poise [13]. In this study, it was found that a deﬁciency in GRX2
augmented O2•-/H2O2 release from cardiac mitochondria metabolizing
pyruvate or 2-oxoglutarate, which is consistent with results collected in
other studies [11,12,41]. What is notable in our study is that the same
eﬀects were not observed in liver mitochondria. In liver mitochondria,
it was found that loss of GRX2 induced a signiﬁcant decrease in ROS
release during the oxidation of pyruvate or 2-oxoglutarate due to the
maintenance of OGDH and PDH in an S-glutathionylated state. These
tissue speciﬁc eﬀects may be related to which enzyme(s) serve as the
high capacity site(s) for ROS release in diﬀerent tissues. For instance,
our group identiﬁed OGDH and Complex III as the chief sites for O2•-/
H2O2 release in liver mitochondria, an observation that was conﬁrmed
in the present study [2]. Furthermore, we found in this study that
pyruvate and 2-oxoglutarate produced ~5 times more O2•-/H2O2 in
liver mitochondria when compared to cardiac mitochondria. This falls
in line with the conclusion that OGDH and Complex III are high ca-
pacity sites for ROS release in liver mitochondria. By contrast, Complex
I and III are known as critical ROS sources in cardiac mitochondria [5].
Here, using succinate as a substrate and selective ROS production in-
hibitors, we found that Complex I and III are integral sources of ROS in
cardiac mitochondria, which generated ~4-fold more ROS when com-
pared to liver mitochondria. Furthermore, the observation that myx-
othiazol augmented ROS release from cardiac mitochondria during
pyruvate or 2-oxoglutarate metabolism conﬁrms that Complex I is a
major site for production. Myxothiazol has been documented to aug-
ment ROS release from cardiac mitochondria due to the over reduction
of electron donating centers in Complex I [29,42]. Finally, atpenin A5
decreased ROS release from cardiac mitochondria oxidizing succinate
by ~90%. If Complex II was an important source then ROS release
would have increased due to electron accumulation in the FAD pros-
thetic group of subunit A. Thus, aptenin A5 is inhibiting ROS release by
blocking reverse and forward electron ﬂow to Complexes I and III, re-
spectively (Fig. 1). Collectively, these observations reﬂect the idea that
Complex I is one the major sites for ROS release in cardiac mitochondria
and that GRX2 regulates ROS release from this respiratory complex.
Therefore, these ﬁndings show that 1) GRX2 plays an integral role in
modulating ROS release from major sites of production through re-
versible S-glutathionylation reactions and 2) there are tissue speciﬁc
diﬀerences in regard to which ROS forming sites serve as high capacity
O2•-/H2O2 producers and GRX2 controls ROS release from these speciﬁc
sites.
4.2. GRX2 is required to modulate succinate-induced ROS production
Mitochondria isolated from liver and cardiac tissue of GRX2+/- and
GRX2-/- mice both displayed a signiﬁcant increase in ROS production
when succinate was being oxidized. However, as indicated above suc-
cinate was a more potent driver for ROS release in cardiac tissue, which
is attributed to Complex I and III serving as the major sites for O2•-/
H2O2 release in heart mitochondria. Our ﬁndings have important im-
plications for heart function and disease. As mentioned, this is the ﬁrst
time the impact of GRX2 deﬁciency on mitochondrial O2•-/H2O2 release
from individual sites of production was ever quantiﬁed. Previous re-
ports had found that partial or full deletion of the Grx2 results in the
over S-glutathionylation of the mitochondrial proteome, increased S-
glutathionylation of complex I, and the development of signs of heart
disease including left ventricular hypertrophy, mitochondrial frag-
mentation, ﬁbrosis, and hypertension [11,43]. Intriguingly, these ef-
fects are not associated with oxidative distress or damage [11]. Hy-
drogen peroxide does play an integral role in modulating myocardial
contraction and relaxation but the over-oxidation of protein cysteine
switches due to high ROS has also been implicated in heart and car-
diovascular disease [44]. Based on our ﬁndings, we propose that GRX2
plays a vital role in controlling how much H2O2 is released from
Complex I for myocardial signaling and that disabling GRX2 activity
compromises redox signaling in cardiomyocytes inducing contractile
dysfunction and metabolic inﬂexibility. It may also be required to
modulate how much is released from Complex III, which was recently
identiﬁed as a target for protein S-glutathionylation [19]. Finally, we
cannot discount that the absence of GRX2 will also inhibit ATP syn-
thase, a known target for S-glutathionylation. In this case, the S-glu-
tathionylation of ATP synthase could augment ROS production by de-
creasing proton return and electron ﬂow through the respiratory chain
[45].
4.3. GRX2 has opposing eﬀects on respiration in liver and cardiac
mitochondria
Mitochondrial ROS release also relies on the same electron transfer
Table 3
Comparison of the O2•-/H2O2 emission rates from cardiac and liver mitochondria oxi-
dizing 2-oxoglutarate. 2-way ANOVA with a Fisher's LSD post-hoc test. n = 4–5,
mean± SEM. pmol min-1 mg of protein-1.
WT GRX2+/- GRX2-/-
Liver 464.72± 11.20 365.50±45.63* 368.11± 34.26*
Cardiac 65.71± 14.44### 150.17±14.58*, ## 194.24± 11.23*, ##
* corresponds to comparison between genotype, # corresponds to comparison between
tissues within genotype. p ≤ 0.05 = * or #, p ≤ 0.01 = ##, p ≤ 0.001.
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pathways utilized for respiration and ATP production. Therefore, we
also examined respiratory capacity in GRX2 deﬁcient mitochondria.
Cardiac mitochondria displayed a ~50% drop in state 3 respiration,
consistent with ﬁndings in a previous study [11]. This is also in line
with the observation that loss of GRX2 augments ROS release due to the
S-glutathionylation and inhibition of Complex I [11]. Therefore, the
lack of control over S-glutathionylation reactions in cardiac mi-
tochondria compromises electron ﬂow through the respiratory chain
resulting in the over reduction of electron donating centers increasing
O2•-/H2O2 production while simultaneously compromising ATP pro-
duction. Deletion of the Grx2 gene had the opposite eﬀect on liver
mitochondria. In fact, it was found that mitochondria isolated from the
liver of mice heterozygous for GRX2 displayed increased state 3 re-
spiration. We are unsure as to why the partial loss of GRX2 would
augment phosphorylating respiration. However, it is possible that a
50% decrease in the availability of this protein may force mitochondria
to adopt a hyperfused state increasing respiration [46]. In addition, in
contrast to cardiac mitochondria, our results indicate that GRX2 is not
integral for regulating phosphorylating respiration in the liver. The
complete knockout of the Grx2 gene did not alter state 3 respiration
relative to WT mitochondria. This could be due to an unidentiﬁed
system that compensates for the disabling of GRX2 function in liver
mitochondria. Indeed, liver mitochondria are enriched with a number
of systems that are required to maintain redox poise and balance since
hepatocytes are naturally exposed to high levels of ROS. Therefore, it
may be that another antioxidant system involved in maintaining redox
poise, like the glutathione S-transferase system, may compensate for the
loss of GRX2 in liver mitochondria. Unfortunately, the function of
glutathione S-transferase systems in modulating the S-glutathionylation
of proteins in mitochondria still has not been examined.
5. Conclusions
Our results demonstrate for the ﬁrst time that GRX2 is required to
regulate O2•-/H2O2 release in liver and cardiac mitochondria. In liver,
major sites for GRX2 action were found to be OGDH and PDH, ob-
servations that were consistent with previous ﬁndings showing that
both enzyme complexes are targeted for S-glutathionylation. By con-
trast, diﬀerent inhibitor and substrate combinations identiﬁed Complex
I was the major GRX2 regulatory target in cardiac tissue. In aggregate,
our ﬁndings indicate that GRX2 is integral for controlling ROS release
from mitochondria in diﬀerent tissues.
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